Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sriparna Ghosal headshot

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

by Sriparna Ghosal

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

by Zacks Equity Research

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

Allscripts Expands Partnership With PIH Health Through 2025

by Zacks Equity Research

Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

by Zacks Equity Research

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $235.06, moving -0.33% from the previous trading session.

ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View

by Zacks Equity Research

ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.

Here's Why You Should Add Cerner (CERN) to Your Portfolio

by Zacks Equity Research

Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion in the fourth quarter.

Here's Why You Should Hold on to AngioDynamics Stock Now

by Zacks Equity Research

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed at $233.23 in the latest trading session, marking a +0.77% move from the prior day.

Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall

by Zacks Equity Research

Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (DXCM) Outperforming Other Medical Stocks This Year?

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.

Here's Why You Should Hold on to Becton, Dickinson Stock Now

by Zacks Equity Research

Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.

Sweta Killa headshot

Top-Ranked ETFs, Stocks From Top Sector of the Last Decade

by Sweta Killa

Amid a plethora of challenges, Wall Street was on a spectacular run over the last decade, rising from the depths of the financial crisis and Great Recession.

Here's Why You Should Hold on to Intuitive Surgical for Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.

Here's Why You Should Invest in Patterson Companies Stock Now

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

    Trina Mukherjee headshot

    6 MedTech Stocks That are Set to Beat the Market in 2020

    by Trina Mukherjee

    Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

    Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (DXCM) Outperforming Other Medical Stocks This Year?

    Here's Why You Should Add DexCom (DXCM) to Your Portfolio

    by Zacks Equity Research

    DexCom (DXCM) raises its 2019 revenue and EPS guidance.

    DexCom (DXCM) Up 16.5% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (DXCM) Outperforming Other Medical Stocks This Year?